Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

Company Update - Anavex Life Sciences Corp announced the acceptance of a peer-reviewed manuscript titled "Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial" in a medical journal focused on Alzheimer's disease, with an expected publication date around Q4 2024/Q1 2025 [1] - The company is on track for regulatory submission of oral blarcamesine in Europe (EMA) in Q4 2024 [2] - Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and Phase 2/3 studies in Rett syndrome [4] - ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies demonstrating potential to halt and/or reverse Alzheimer's disease progression [4] - ANAVEX®3-71, another clinical-stage drug candidate, targets SIGMAR1 and M1 muscarinic receptors and has shown disease-modifying activity against major hallmarks of Alzheimer's disease in preclinical trials [4] Alzheimer's Disease Market - There are an estimated 7 million people in Europe with Alzheimer's disease, a number expected to double by 2030 [3] - The World Health Organization estimated the cost of caring for people with dementia, including Alzheimer's disease, in Europe at $439 billion in 2019, or $31,144 per person [3] Company Overview - Anavex Life Sciences Corp is a publicly traded biopharmaceutical company focused on developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other CNS diseases [4] - The company's drug candidates have shown potential in treating additional CNS disorders, including epilepsy, based on preclinical studies [4] - Anavex received a research grant from The Michael J Fox Foundation for Parkinson's Research to develop ANAVEX®2-73 for Parkinson's disease treatment [4]